BioLineRx (BLRX) Operating Income (2013 - 2025)

BioLineRx's Operating Income history runs 13 years deep, the most recent figure standing at -$3.4 million for Q4 2025.

• In Q4 2025, Operating Income rose 23.5% year-over-year to -$3.4 million; the TTM figure through Dec 2025 stood at -$10.3 million (up 49.59% YoY), while the FY2025 annual figure was -$10.3 million, up 49.59% from the prior year.
• Operating Income was -$3.4 million for Q4 2025 at BioLineRx, down from -$2.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$2.2 million in Q3 2025 to a low of -$18.6 million in Q4 2023.
• Historically, Operating Income has averaged -$6.7 million across 5 years, with a median of -$6.1 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Operating Income sank 121.08% in 2023, then jumped 76.16% in 2024.
• A 5-year view of Operating Income shows it stood at -$6.6 million in 2021, then fell by 27.28% to -$8.4 million in 2022, then tumbled by 121.08% to -$18.6 million in 2023, then surged by 76.16% to -$4.4 million in 2024, then gained by 23.5% to -$3.4 million in 2025.
• The last three Operating Income figures came in at -$3.4 million (Q4 2025), -$2.2 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.